Adamas Pharmaceuticals (NASDAQ: ADMS) recently received a number of ratings updates from brokerages and research firms:

  • 8/25/2017 – Adamas Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Cowen and Company. They now have a $55.00 price target on the stock, up previously from $45.00.
  • 8/25/2017 – Adamas Pharmaceuticals had its “outperform” rating reaffirmed by analysts at JMP Securities. They now have a $33.00 price target on the stock, up previously from $29.00.
  • 8/25/2017 – Adamas Pharmaceuticals had its “ourperform” rating reaffirmed by analysts at William Blair.
  • 8/23/2017 – Adamas Pharmaceuticals was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 8/17/2017 – Adamas Pharmaceuticals was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 8/11/2017 – Adamas Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing ADS-5102, its lead wholly-owned product candidate, for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson’s disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The company’s portfolio also includes Namzaric and Namenda XR, two approved products with Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc. Forest is responsible for marketing both products in the United States under an exclusive license from Adamas. “
  • 8/9/2017 – Adamas Pharmaceuticals was given a new $45.00 price target on by analysts at Cowen and Company. They now have a “buy” rating on the stock.
  • 8/9/2017 – Adamas Pharmaceuticals had its “buy” rating reaffirmed by analysts at Noble Financial.
  • 8/5/2017 – Adamas Pharmaceuticals was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 7/19/2017 – Adamas Pharmaceuticals was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 7/11/2017 – Adamas Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing ADS-5102, its lead wholly-owned product candidate, for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson’s disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The company’s portfolio also includes Namzaric and Namenda XR, two approved products with Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc. Forest is responsible for marketing both products in the United States under an exclusive license from Adamas. “

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) traded down 4.70% during mid-day trading on Wednesday, reaching $20.66. The company’s stock had a trading volume of 588,753 shares. Adamas Pharmaceuticals, Inc. has a 12-month low of $12.10 and a 12-month high of $21.80. The stock’s market cap is $465.14 million. The firm’s 50 day moving average price is $16.54 and its 200 day moving average price is $16.78.

Adamas Pharmaceuticals (NASDAQ:ADMS) last released its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.93) EPS for the quarter, missing the consensus estimate of ($0.81) by $0.12. Adamas Pharmaceuticals had a negative net margin of 10,499.65% and a negative return on equity of 52.91%. The company had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.03 million. During the same period last year, the business earned ($0.78) earnings per share. The company’s revenue for the quarter was down 90.9% compared to the same quarter last year. On average, equities analysts predict that Adamas Pharmaceuticals, Inc. will post ($3.79) earnings per share for the current year.

In other Adamas Pharmaceuticals news, major shareholder Great Point Partners Llc sold 350,000 shares of the firm’s stock in a transaction dated Monday, June 19th. The stock was sold at an average price of $17.05, for a total value of $5,967,500.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders sold 731,041 shares of company stock worth $12,476,149 over the last three months. 29.00% of the stock is currently owned by corporate insiders.

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.

Receive News & Ratings for Adamas Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.